Researchers develop mouse models of neurofibromatosis

December 09, 1999

December 10, 1999--Two strains of mice genetically engineered to develop neurofibromatosis type 1 (NF1), a tumor-producing hereditary disease of the peripheral nerves, are likely to improve understanding of the progression of NF1 and provide much needed models in which to evaluate therapies for the disease.

NF1, also called von Recklinghausen's disease, occurs in about one in every 3,500 births. The disorder can cause thousands of painful, disfiguring skin lesions and benign peripheral nerve tumors, called neurofibromas. In some cases, those neurofibromas can turn malignant, rendering the disease potentially deadly.

The research team, which was led by HHMI investigator Tyler Jacks and postdoctoral fellow Karen Cichowski of the Massachusetts Institute of Technology, announced in the December 10, 1999, issue of the journal Science that it had produced one set of mice with benign NF1-related tumors and a second set of mice that developed the malignant tumors associated with the disease.

In developing the mouse models, the researchers began with a previously produced strain of NF1 "heterozygous" mice that were missing one functioning copy of the gene. The NF1 gene codes for the protein neurofibromin, which is normally a tumor suppressor, preventing cells from proliferating. "Since this first heterozygous animal did prove to be cancer-prone, we knew we had a connection to the human disease," said Jacks. "However, those animals did not develop the hallmark lesions of NF1." Mice lacking both copies of the NF1 gene died in utero. In order to create mutant mice that would survive, Jacks and his colleagues produced chimeric mice - animals containing a mix of cells that had either both functioning NF1 genes or no NF1 genes at all.

When the scientists produced the chimeric mice, the animals showed benign neurofibromas, in particular, tumors in deep nerves that are more likely to turn malignant. Importantly, said Jacks, the chimeric mice with higher percentages of NF1-deficient cells showed higher degrees of NF1 pathology.

The researchers also followed the fate of cells lacking NF1 by using a "reporter gene" to track cells missing the NF1 genes. Those experiments revealed that neurofibroma tumors invariably included such NF1-deficient cells.

"This finding was important because these tumors include many types of cells, and it has been unclear whether the hyperproliferative cells - those that comprise the tumor - were NF1-deficient. Our work suggests that the tumor cells are, indeed, NF1-deficient."

Also, said Jacks, electron microscopy of the tumors revealed that they closely resemble human tumors.

"When we showed those microscopy images to neuropathologists, they were very impressed that we had tumors composed of cells characteristic of human tumors," said Jacks. Thus, he said, the mouse model will likely be useful not only in understanding NF1, but in testing gene therapies or drugs to treat the benign tumors.

In creating the mouse model of the malignant tumors, the scientists crossed their heterozygous mice with a strain of mice lacking another tumor-suppressor gene, called p53.

"We found that mice defective in only NF1 or p53 did not produce this type of malignant tumor, but we did see these tumors at high frequency in mice carrying the two mutations together," said Jacks. "Given this high frequency and the rapid development of tumors, we believe we have a robust model of this malignant tumor that will likely be useful in evaluating therapies."

According to Jacks, a number of drug companies are developing drugs to treat cancers by blocking a key cancer gene called Ras, which is also controlled by NF1. Thus, such anti-Ras drugs might be also prove useful in treating NF1.

Of particular interest to Jacks and his colleagues is the observation that the mutant mice showed differences in pathology when the NF1 and p53 mutations were on the same or opposite chromosomes.

"Animals with both mutations on the same chromosome developed tumors much more quickly," he said. "So, we can argue quite strongly that linkage of two genes is important in cancer modeling in mice and perhaps in humans." Such linkage means that damage to or loss of a portion of one chromosome that knocks out both genes may be a significant general cancer-causing mechanism, said Jacks.

In future studies, the researchers plan to test anti-tumor drugs on their mouse models, as well as produce mice in which NF1 is deleted in specific types of nerve cells. Targeting such cells will enable more detailed study of the mechanism of tumor production, said Jacks. The scientists also plan to produce NF1 and p53 mutations in different strains of mice to determine whether other genetic factors might subtly modify the progress of the disease.

"If we find such modifiers, we might better understand the functions of these genes and also why different patients develop different symptoms of the disease," said Jacks.

Howard Hughes Medical Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to